Thera-SAbDab

BASILIXIMAB

>   Structural Summary
TherapeuticBasiliximab
TargetIL2RA
Heavy ChainQVQLQQSGTVLARPGASVKMSCKASGYSFTRYWMHWIKQRPGQGLEWIGAIYPGNSDTSYNQKFEGKAKLTAVTSASTAYMELSSLTHEDSAVYYCSRDYGYYFDFWGQGTTLTVSS
Light ChainQIVSTQSPAIMSASPGEKVTMTCSASSSRSYMQWYQQKPGTSPKRWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCHQRSSYTFGGGTKLEIK
100% seqID Fv Structure1mim [Fvs: HL], 3iu3 [Fvs: AB, CD, HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)NFD
Recorded Developmental Technologyna
INN Year Proposed1996
INN Year Recommended1997
Companies InvolvedCerimon Pharmaceuticals, Novartis
Conditions ApprovedRenal transplant rejection, Transplant rejection
Conditions Activena
Conditions DiscontinuedUlcerative colitis, Uveitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]